New radiation regimen aims to cut prostate cancer treatment time
NCT ID NCT00809991
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 study tested a radiation therapy plan that gives a slightly higher dose each day over fewer sessions (16 days instead of the usual 8-9 weeks) for men with early-stage prostate cancer. The goal was to see if this shorter schedule is safe and effective, while also tracking quality of life and side effects. 91 men with low-risk prostate cancer participated, and researchers measured urinary, bowel, and sexual function over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
radiation therapy (hypofractionated, image-guided)
What this could lead to
If successful, this could offer a more convenient and equally effective radiation schedule for men with early-stage prostate cancer.
What could go wrong
This is a small Phase 2 study, so results may not apply to all patients. The higher daily dose could increase side effects like urinary or bowel issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Johns Hopkins University School of Medicne
Baltimore, Maryland, 21231, United States